The annual cost of Inqovi (decitabine and cedazuridine) can vary. It is important to note that the drug's list price does not reflect the actual amount paid by patients or insurers due to rebates and discounts.
How much does Inqovi cost without insurance?
Without insurance, the out-of-pocket cost for Inqovi can be substantial. For example, a 30-day supply might cost around $12,500 [1].
What financial assistance programs are available for Inqovi?
Astellas, the manufacturer of Inqovi, offers patient assistance programs that can help reduce out-of-pocket costs for eligible individuals. The Astellas Patient Assistance Program provides free medication to uninsured patients who meet certain income requirements. Additionally, co-pay assistance programs may be available for commercially insured patients [1, 2].
How does Inqovi's cost compare to other myelodysplastic syndrome treatments?
The cost of Inqovi is in line with other medications used to treat myelodysplastic syndromes (MDS). Treatment costs for MDS can be high, and financial assistance and insurance coverage are often crucial for patients.
When does Inqovi's patent expire?
Information on Inqovi's patent expiration is available on DrugPatentWatch.com [3]. Patents protect a drug's exclusivity, influencing its price and the potential for generic competition.
What is Inqovi used to treat?
Inqovi is a combination of decitabine and cedazuridine, indicated for adult patients with myelodysplastic syndromes (MDS), including certain types of chronic myelomonocytic leukemia (CMML) [1].
How does Inqovi work?
Inqovi works by reducing the number of DNA changes in cancer cells, which can help these cells mature into normal blood cells [1].
Sources:
1. https://www.inqovi.com/patient/cost-and-support
2. https://www.astellas.com/us/patients/assistance
3. https://www.drugpatentwatch.com/